State of the Neoadjuvant Therapy for Glioblastoma Multiforme-Where Do We Stand?

Overview

Journal Neurooncol Adv

Publisher Oxford University Press

Date 2024 Apr 1

PMID 38560349

Authors

Naeim Nabian

Reza Ghalehtaki

Mehdi Zeinalizadeh

Carmen Balana

Paola Anna Jablonska

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults. Despite several investigations in this field, maximal safe resection followed by chemoradiotherapy and adjuvant temozolomide with or without tumor-treating fields remains the standard of care with poor survival outcomes. Many endeavors have failed to make a dramatic change in the outcomes of GBM patients. This study aimed to review the available strategies for newly diagnosed GBM in the neoadjuvant setting, which have been mainly neglected in contrast to other solid tumors.

Citing Articles

Discovery of mutated oncodriver genes associated with glioblastoma originated from stem cells of subventricular zone through whole exome sequence profile analysis, and drug repurposing.

Sarker A, Uddin B, Ahmmed R, Mahmud S, Ajadee A, Pappu M Heliyon. 2025; 11(2):e42052.

PMID: 39906820 PMC: 11791140. DOI: 10.1016/j.heliyon.2025.e42052.

LDH Isoenzyme and GAA-BSA Nanoparticles: A Novel Therapy Approach for Proneural Subtype Glioblastoma Multiforme.

Yang M, Han X, Li H, Du F, Feng C, Gong A J Cancer. 2025; 16(4):1101-1117.

PMID: 39895794 PMC: 11786042. DOI: 10.7150/jca.98452.

Postoperative NEOadjuvant TEMozolomide followed by chemoradiotherapy versus upfront chemoradiotherapy for glioblastoma multiforme (NEOTEM) trial: Interim results.

Sharifian A, Kazemian A, Farzin M, Amirkhani N, Farazmand B, Naderi S Neurooncol Adv. 2024; 6(1):vdae195.

PMID: 39664679 PMC: 11632829. DOI: 10.1093/noajnl/vdae195.

References

Razis E, Selviaridis P, Labropoulos S, Norris J, Zhu M, Song D . Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009; 15(19):6258-66. DOI: 10.1158/1078-0432.CCR-08-1867. View

Peters K, Lou E, Desjardins A, Reardon D, Lipp E, Miller E . Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. Oncologist. 2015; 20(7):727-8. PMC: 4492239. DOI: 10.1634/theoncologist.2015-0135. View

Barrie M, Couprie C, Dufour H, Figarella-Branger D, Muracciole X, Hoang-Xuan K . Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme. Ann Oncol. 2005; 16(7):1177-84. DOI: 10.1093/annonc/mdi225. View

Woodworth G, McGirt M, Samdani A, Garonzik I, Olivi A, Weingart J . Accuracy of frameless and frame-based image-guided stereotactic brain biopsy in the diagnosis of glioma: comparison of biopsy and open resection specimen. Neurol Res. 2005; 27(4):358-62. DOI: 10.1179/016164105X40057. View

Saenz-Antonanzas A, Auzmendi-Iriarte J, Carrasco-Garcia E, Moreno-Cugnon L, Ruiz I, Villanua J . Liquid Biopsy in Glioblastoma: Opportunities, Applications and Challenges. Cancers (Basel). 2019; 11(7). PMC: 6679205. DOI: 10.3390/cancers11070950. View

Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R . Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17):1731-40. DOI: 10.1056/NEJMoa040694. View

de Robles P, Fiest K, Frolkis A, Pringsheim T, Atta C, St Germaine-Smith C . The worldwide incidence and prevalence of primary brain tumors: a systematic review and meta-analysis. Neuro Oncol. 2014; 17(6):776-83. PMC: 4483114. DOI: 10.1093/neuonc/nou283. View

Shoaf M, Desjardins A . Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice. Neurotherapeutics. 2022; 19(6):1818-1831. PMC: 9723031. DOI: 10.1007/s13311-022-01256-1. View

Roa W, Kepka L, Kumar N, Sinaika V, Matiello J, Lomidze D . International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme. J Clin Oncol. 2015; 33(35):4145-50. DOI: 10.1200/JCO.2015.62.6606. View

10.

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View

11.

Bogsrud T, Londalen A, Brandal P, Leske H, Panagopoulos I, Borghammer P . 18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma. Clin Nucl Med. 2019; 44(8):605-611. DOI: 10.1097/RLU.0000000000002641. View

12.

Wen P, Packer R . The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. Neuro Oncol. 2021; 23(8):1215-1217. PMC: 8328017. DOI: 10.1093/neuonc/noab120. View

13.

Gilbert M, Friedman H, Kuttesch J, Prados M, Olson J, Reaman G . A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol. 2002; 4(4):261-7. PMC: 1920664. DOI: 10.1093/neuonc/4.4.261. View

14.

Pfeiffer P, Qvortrup C, Hansen K . How to select cancer patients for immunotherapy. EBioMedicine. 2021; 63:103184. PMC: 7804597. DOI: 10.1016/j.ebiom.2020.103184. View

15.

Baik S, Kim S, Na Y, Cho J . Supratotal Resection of Glioblastoma: Better Survival Outcome than Gross Total Resection. J Pers Med. 2023; 13(3). PMC: 10053695. DOI: 10.3390/jpm13030383. View

16.

Sawlani V, Patel M, Davies N, Flintham R, Wesolowski R, Ughratdar I . Multiparametric MRI: practical approach and pictorial review of a useful tool in the evaluation of brain tumours and tumour-like lesions. Insights Imaging. 2020; 11(1):84. PMC: 7367972. DOI: 10.1186/s13244-020-00888-1. View

17.

Haddad P, Ghalehtaki R, Saeedian A, Farhan F, Babaei M, Aghili M . Current approaches in intensification of long-course chemoradiotherapy in locally advanced rectal cancer: a review. Radiat Oncol J. 2021; 39(2):83-90. PMC: 8497854. DOI: 10.3857/roj.2021.00108. View

18.

Tarhini A, Eads J, Moore K, Tatard-Leitman V, Wright J, Forde P . Neoadjuvant immunotherapy of locoregionally advanced solid tumors. J Immunother Cancer. 2022; 10(8). PMC: 9386211. DOI: 10.1136/jitc-2022-005036. View

19.

Mao Y, Yao Y, Zhang L, Lu Y, Chen Z, Zhang J . Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial. Chin Med J (Engl). 2015; 128(20):2751-8. PMC: 4736883. DOI: 10.4103/0366-6999.167313. View

20.

Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H . Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†. Ann Oncol. 2014; 25(7):1442-1447. DOI: 10.1093/annonc/mdu148. View